Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
about
The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapyFit for the Eye: Aptamers in Ocular DisordersImmediate effect of intravitreal injection of bevacizumab on intraocular pressure.Recent advances in the management of neovascular glaucoma.Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment.Lasting controversy on ranibizumab and bevacizumab.Intraocular Pressure Changes in Non-Glaucomatous Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Agents.Sustained Elevation of Intraocular Pressure Associated with Intravitreal Administration of Anti-vascular Endothelial Growth Factor: A Systematic Review and Meta-AnalysisElectroretinographic evaluations of retinal function before, just after, and after intravitreal injections.Effect of prophylactic intraocular pressure-lowering medication (brinzolamide) on intraocular pressure after ranibizumab intravitreal injection: A case-control study.Treatments for macular oedema following central retinal vein occlusion: systematic review.Changes in intraocular pressure in study and fellow eyes in the IVAN trial.Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab.VEGF as a Paracrine Regulator of Conventional Outflow Facility.Ranibizumab for age-related macular degeneration.Ocular hypertension following intravitreal anti-vascular endothelial growth factor agents.Incidence and management of elevated intraocular pressure with antivascular endothelial growth factor agents.Aptamers as targeted therapeutics: current potential and challenges.Association of Repeated Intravitreous Bevacizumab Injections With Risk for Glaucoma Surgery.Use of Anti-VEGF Agents in Glaucoma Surgery.Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast CancerQuality of bevacizumab compounded for intravitreal administration.Zeaxanthin inhibits hypoxia-induced VEGF secretion by RPE cells through decreased protein levels of hypoxia-inducible factors-1α.Serum concentration of vascular endothelial growth factor after bilateral intravitreal injection of bevacizumab.Real-time measurement of needle forces and acute pressure changes during intravitreal injections.Chemical modifications of nucleic acid drugs and their delivery systems for gene-based therapy.Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration.Hypoxia-induced vascular endothelial growth factor secretion by retinal pigment epithelial cells is inhibited by melatonin via decreased accumulation of hypoxia-inducible factors-1α protein.Effects of intravitreal injection of bevacizumab with or without anterior chamber paracentesis on intraocular pressure and peripapillary retinal nerve fiber layer thickness: a prospective study.Aptamers as Diagnostic Tools in Cancer
P2860
Q28067341-83AF2157-07FE-4313-A8F0-12A88E9444B5Q28828283-9A34B467-445F-4E93-B417-34B9705CC9A0Q33968693-EAAAF2FF-120F-4A35-8BC6-671945BD5803Q34734475-2FF00809-571F-4455-94DC-DDA17F3F3049Q35568276-F0E24A37-7AC5-4DB5-8709-04A9DCDBE7EAQ35641933-1006CE39-5B3D-4EE8-845A-7698CD1E0523Q35770567-31838C3F-34E0-4C16-9784-6B8F7CF4ED88Q36230124-0E9B6954-664E-4308-A9E3-3738C650343CQ37153890-BA94C4CC-018C-4815-9A7D-C63BFE912757Q37517747-CC050E3F-3A24-41E7-BCE1-9F66EE956C8DQ37590692-D87D5E6B-2268-4B16-9A21-49258AAA9576Q37600185-995D4875-3DFA-44CA-8959-78A092E970FCQ37708813-6CBE8E06-8C37-47DF-8072-9DB24F88EB03Q37731916-5C77D79A-B355-4D4F-A5F1-58F835E83D8AQ37981760-E1BB4560-A3EC-4768-B737-56FA22E78B80Q38062429-FEFFBCDB-DE0D-44D2-9117-2D277AD0094CQ38103031-1CED4FAB-7067-4E9E-82E2-A93D46076031Q38290290-E5D74442-691B-4A83-AEDA-B0337EDBCD4CQ38402203-F24C7244-31A2-47D7-A4BC-2B2565D6578EQ41320402-612135CE-3210-4D60-BC8E-1BF2F23A9487Q41661268-37CB8F75-9987-4989-8B97-9E02008B7B29Q41816126-6920400C-D5B8-4CBA-BAB5-6839A54886B5Q41843418-58CEF363-5CD6-418E-8959-D6E45CFC35E4Q41914288-60CBC7CE-D438-44B5-BDB4-114B63BCADAAQ48063486-F9D07583-11DD-4A72-BAF5-19D6FCE7FAA3Q48282746-0FE6A763-5D05-4CD2-A927-1B9BF732ADDBQ50763443-42994187-7EE0-4F92-8559-253FC179AEB4Q51645214-AC3D74D0-86CC-4878-926A-6A85D71E3DBAQ54999099-A50C50B5-BBB5-44DD-92A2-EB804523ED76Q58749805-D8F37DAB-F419-4CFA-BB4B-8BC06DD60A70
P2860
Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Sustained elevated intraocular ...... , ranibizumab, and pegaptanib.
@en
Sustained elevated intraocular ...... , ranibizumab, and pegaptanib.
@nl
type
label
Sustained elevated intraocular ...... , ranibizumab, and pegaptanib.
@en
Sustained elevated intraocular ...... , ranibizumab, and pegaptanib.
@nl
prefLabel
Sustained elevated intraocular ...... , ranibizumab, and pegaptanib.
@en
Sustained elevated intraocular ...... , ranibizumab, and pegaptanib.
@nl
P2093
P1433
P1476
Sustained elevated intraocular ...... , ranibizumab, and pegaptanib.
@en
P2093
Colin A McCannel
Daniel Y Choi
Maria Carolina Ortube
Michael B Gorin
Tara A McCannel
P304
P356
10.1097/IAE.0B013E318217FFDE
P577
2011-06-01T00:00:00Z